336 related articles for article (PubMed ID: 15483014)
41. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.
Wahlin BE; Aggarwal M; Montes-Moreno S; Gonzalez LF; Roncador G; Sanchez-Verde L; Christensson B; Sander B; Kimby E
Clin Cancer Res; 2010 Jan; 16(2):637-50. PubMed ID: 20068089
[TBL] [Abstract][Full Text] [Related]
42. B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity.
Selmayr M; Menzel H; Kremer JP; Thierfelder S; Mocikat R
Cancer Gene Ther; 2000 Mar; 7(3):501-6. PubMed ID: 10766357
[TBL] [Abstract][Full Text] [Related]
43. Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness.
Ashour AK; Petersen JL; McIlhaney MM; Vose JM; Solheim JC
Hybridoma (Larchmt); 2006 Oct; 25(5):306-8. PubMed ID: 17044787
[TBL] [Abstract][Full Text] [Related]
44. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
45. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.
Calemma R; Ottaiano A; Trotta AM; Nasti G; Romano C; Napolitano M; Galati D; Borrelli P; Zanotta S; Cassata A; Castello G; Iaffaioli VR; Scala S
J Transl Med; 2012 Nov; 10():232. PubMed ID: 23171437
[TBL] [Abstract][Full Text] [Related]
46. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
[TBL] [Abstract][Full Text] [Related]
47. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism.
Li SC; Chen YC; Evens AM; Lee CC; Liao HF; Yu CC; Tung YT; Su YC
Am J Hematol; 2010 Oct; 85(10):810-2. PubMed ID: 20730791
[TBL] [Abstract][Full Text] [Related]
48. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes.
Jönsen A; Gunnarsson I; Gullstrand B; Svenungsson E; Bengtsson AA; Nived O; Lundberg IE; Truedsson L; Sturfelt G
Rheumatology (Oxford); 2007 Sep; 46(9):1417-21. PubMed ID: 17596285
[TBL] [Abstract][Full Text] [Related]
49. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
[TBL] [Abstract][Full Text] [Related]
50. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
[TBL] [Abstract][Full Text] [Related]
51. Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis.
Thabet MM; Huizinga TW; Marques RB; Stoeken-Rijsbergen G; Bakker AM; Kurreeman FA; White SJ; Toes RE; van der Helm-van Mil AH
Ann Rheum Dis; 2009 Nov; 68(11):1775-80. PubMed ID: 19019892
[TBL] [Abstract][Full Text] [Related]
52. Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.
Koumarianou A; Kountourakis P; Economopoulos T
J Steroid Biochem Mol Biol; 2008 Apr; 109(3-5):230-2. PubMed ID: 18406604
[TBL] [Abstract][Full Text] [Related]
53. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
54. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
55. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
56. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma.
Wang SS; Cerhan JR; Hartge P; Davis S; Cozen W; Severson RK; Chatterjee N; Yeager M; Chanock SJ; Rothman N
Cancer Res; 2006 Oct; 66(19):9771-80. PubMed ID: 17018637
[TBL] [Abstract][Full Text] [Related]
57. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.
Al-Tourah AJ; Gill KK; Chhanabhai M; Hoskins PJ; Klasa RJ; Savage KJ; Sehn LH; Shenkier TN; Gascoyne RD; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5165-9. PubMed ID: 18838711
[TBL] [Abstract][Full Text] [Related]
58. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
Bendandi M
Expert Rev Anticancer Ther; 2001 Jun; 1(1):65-72. PubMed ID: 12113135
[TBL] [Abstract][Full Text] [Related]
59. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
Weng WK; Negrin RS; Lavori P; Horning SJ
J Clin Oncol; 2010 Jan; 28(2):279-84. PubMed ID: 19933905
[TBL] [Abstract][Full Text] [Related]
60. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
